Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 38

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 38
---
idends on performance shares accrue during the performance period and are paid at vesting only to the extent that shares are earned. |

| ● | Performance-Vested Restricted Stock Units (40% of total LTI award)—These awards have the potential to vest at 0% to 200% of target in one-third increments during a three-year performance period and are earned based on AbbVie’s return on invested capital (ROIC) relative to a group made up of companies that are constituents in either the S&P Pharmaceutical, Biotech, and Life Science Index or the NYSE Arca Pharmaceutical Index. Dividends accrue during the performance period and are paid at vesting only to the extent that shares are earned. |

| ● | Non-Qualified Stock Options (20% of total LTI award)—These awards have the potential to vest in one-third increments on each of the first three annual anniversaries of the grant date, subject to continued employment with the company. The option exercise price is set at or above fair market value on the grant date. To the extent that the options vest, the award expires ten years after the grant date. |

Performance Share and Performance-Vested Restricted Stock Unit Targets and Results Performance targets and results associated with the 2024 awards of performance shares and 2022-2024 awards of performance-vested restricted stock units are shown below. Relative TSR results for the performance shares are in progress; these results and their impact on final payout will be disclosed following the completion of the three-year performance period.

| Performance Objective and Impact on Payout |   |                                                                        Threshold |   |      Target |   |    Maximum |   |     Result |   | Impact on Payout |
| Performance Shares                         |   |                                                                                  |   |             |   |            |   |            |   |                  |
| 2024 Adjusted Diluted EPS(1,2)             | ​ |                                                                            $9.58 | ​ |       $9.63 | ​ |      $9.83 | ​ |     $10.12 | ​ | 200%             |
| EPS Impact on Payout                       | ​ |                                                                              50% | ​ |        100% | ​ |       200% | ​ |          ​ | ​ | ​                |
| 2024-2026 Relative TSR                     | ​ | Relative TSR is measured over a 3-year performance period and used as a modifier |   |             |   |            |   |            |